Represents the value of the Company's equity securities sold to institutional accredited investors in a private financing, available for purchase by the lender within one year after the closing of the Loan Agreement. Debt Instrument Lender Option To Purchase Equity Securities Value of the Company's equity securities available for purchase by the lender Debt Instrument Lender Option To Purchase Equity Securities Period Period to purchase equity securities sold to institutional accredited investors under the Loan Agreement Represents the period to purchase equity securities sold to institutional accelerated investors under the Loan Agreement. Operating Lease Amendment Additional Space Additional space that the entity will occupy under the amended lease agreement Represents the additional space that the entity will occupy under the amended lease agreement. Operating Lease Amendment Aggregate Space Aggregate space that the entity will occupy under the amended lease agreement Represents the aggregate space that the entity will occupy under the amended lease agreement. Operating Lease Amendment Lease Term Lease term Represents the period of lease under the amended lease agreement. Operating Leases Reimbursement for Tenant Improvements in Remainder of Fiscal Year Reimbursement for tenant improvements agreed by landlord in 2012 Represents the amount of tenant improvements to be reimbursed by the landlord under the lease agreement during remainder of the current fiscal year. Operating Leases Maximum Reimbursement for Tenant Improvements in Fiscal Year Two Reimbursement for tenant improvements agreed by landlord in 2013 Represents the amount of tenant improvements to be reimbursed by the landlord under the lease agreement within the second year from the balance sheet date. Operating Leases Maximum Reimbursement for Tenant Improvements in Fiscal Year Three Reimbursement for tenant improvements agreed by landlord in 2014 Represents the amount of tenant improvements to be reimbursed by the landlord under the lease agreement within the third year from the balance sheet date. Operating Leases Reimbursement for Tenant Improvements Recorded in Prepaid Expenses and Other Current Assets Reimbursement for tenant improvements agreed by landlord recorded in prepaid expenses and other current assets with offsetting entry to deferred lease benefits Represents the amount of reimbursement for tenant improvements agreed by the landlord recorded in prepaid expenses and other current assets with an offsetting entry recorded to deferred lease benefits. Operating Leases Reimbursement for Tenant Improvements Recorded in Other Assets Reimbursement for tenant improvements agreed by landlord recorded in other assets Represents the amount of reimbursement for tenant improvements agreed by the landlord recorded in non-current assets. Amendment Description Operating Leases Reimbursement for Tenant Improvements Recorded in Non Current Assets Reimbursement for tenant improvements agreed by landlord recorded in other assets with offsetting entry to deferred lease benefits Represents the amount of reimbursement for tenant improvements agreed by the landlord recorded in other assets with an offsetting entry recorded to deferred lease benefits. Amendment Flag Operating Lease Amended Lease Renewal Period Option One Additional period of renewal of amended lease with respect to entire leased space, option one Represents the additional period of renewal of amended lease with respect to the entire leased space, option one. Operating Lease Amended Lease Renewal Period Option Two Additional period of renewal of amended lease with respect to entire leased space, option two Represents the additional period of renewal of amended lease with respect to the entire leased space, option two. Tax Incentive Program Number of Employees Pledged to be Hired Number of employees pledged to be hired Represents the number of employees to be hired under the incentive program over a specified period of time. Tax Incentive Program Performance Period Performance period Represents the performance period of the tax incentive program over which the incentive is to be amortized. Tax Incentive Program Benefit Recognized Amount of benefit recognized Represents the portion of tax incentives and grants received under the tax incentive and credit programs, recognized during the period. Debt Instrument Interest Only Payment Period Period of interest-only payment Represents the period of interest-only payment as provided under the loan agreement. Debt Instrument Final Interest Payment Fee required to be paid Represents the amount of final interest payment to be paid under the loan agreement. Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement Payment Triggered Collaborative agreement, payment triggered by Company Represents the payment obligation under the collaboration agreement that was triggered by the Company. Debt Conversion Converted Instrument Discount upon Qualified Equity Financing Discount on conversion price of convertible debt upon qualified equity financing (as a percent) Represents the percentage of discount on conversion price of convertible debt upon qualified equity financing. Schedule of Tax Incentive Programs [Table] Table providing information pertaining to tax incentive and credit programs including the incentives and credits received and recognized, terms of the incentive and credit plans, etc. Tax Incentive Program [Axis] Information by type of tax incentive and credit programs. Tax Incentive Program [Domain] Type of tax incentive and credit programs. Represents information pertaining to tax incentives awarded in 2010 under the Life sciences Tax Incentive program. Life Sciences Tax Incentive Program 2010 [Member] Life Sciences Tax Incentive Program 2010 Document and Entity Information Series F amount Series F Amount. Carrying value as of the balance sheet date of advances from Preferred Stockholders. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Current Fiscal Year End Date Preferred Stock Warrants, Outstanding Convertible preferred stock warrants Represents the fair value written certificate that gives the holder the right to purchase shares of a stock for a specified price within a specified period of time. Remeasurement of convertible preferred stock warrants Represents the unrealized gain or loss on the remeasurement of fair value of preferred stock warrants. Change in fair value of convertible preferred stock warrants Gain (loss) on Mark to Market on Preferred Stock Warrants (Gain) loss on mark-to-market on preferred stock warrants and contingent consideration Represents the amortization of deferred lease benefits and tax incentive of the reporting entity during the reporting period. Amortization of Deferred Lease Benefits and Tax Incentives Amortization of deferred lease benefits and tax incentives Increase (Decrease) Deferred Lease Benefits and Tax Incentive The increase (decrease) during the reporting period in deferred lease benefits and tax incentives yet to be earned and recognized as a reduction of rental expense over the lease term and in the liability reflecting credits yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Deferred lease benefits and tax incentives Increase (Decrease) in Lease Benefits Deferred lease benefits The increase (decrease) during the reporting period in deferred lease benefits yet to be earned and recognized as a reduction of rental expense over the lease term. Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Losses Unrealized losses, Due within 1 year Unrealized Losses Deferred tax incentive Increase (Decrease) in Deferred Credits The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting credits yet to be earned for which cash or other forms of consideration was received or recorded as a receivable. Represents the cash inflows in advance for issuance of convertible preferred stock. Proceeds Received in Advance for Issuance of Common Stock Proceeds received in advance of Series F issuance Reclassification of deferred financing costs to stockholders' equity Represents the amount of deferred financing costs reclassified to stockholders' equity. Deferred Financing Costs Reclassification to Stockholders Equity Deferred financing costs netted against the equity proceeds within stockholders' equity Accrued interest on Series F amount relieved to additional paid-in capital (Note 13) Represents the accrued interest on unissued preferred stock that was relieved to additional paid-in capital in a noncash transaction. Accrued Interest on Preferred Stock Relieved to Additional Paid in Capital Issuance of Shares from Advance Preferred Stock, Amount Issuance of shares from Series F amount (Note 13) Represents the issuance of shares from the amount received in advance in a noncash transaction. Preferred Stock Issuable for Consulting Services Rendered Series F convertible preferred stock issuable for consulting services rendered Represents the convertible preferred stock issuable for consulting services rendered in a noncash transaction. Document Period End Date Preferred Stock Received for Technology License Series C convertible preferred stock received for technology license Represents the convertible preferred stock received for technology license in a noncash transaction. Fair Value of Assets Acquired Included in Accrued Expenses Property and equipment included in ending accrued expenses The fair value of assets acquired in noncash investing or financing activities that were included in ending accrued expenses as of the balance sheet date. Fair Value of Assets Acquired Included in Accounts Payable The fair value of assets acquired in noncash investing or financing activities that were included in ending accounts payable as of the balance sheet date. Property and equipment included in ending accounts payable Initial Public Offering Initial Public Offering Disclosure [Text Block] Initial Public Offering The entire disclosure of initial public offering made by company. License and Collaboration Agreements Accrued Expenses and Other Accrued and Other Current Liabilities Disclosure [Text Block] The entire disclosure for accrued and other current liabilities at the end of the reporting period. Return of Series C stock as a result of license agreement Return of Series C Stock, During Period, Value Equity impact of the value of Series C stock that was returned by stockholders as consideration for a license agreement. Return of Series C Stock, During Period, Shares Number of Shares of Series C stock that was returned by stockholders as consideration for a license agreement. Return of Series C stock as a result of license agreement (in shares) Entity [Domain] Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses Unrealized Losses Issuance of Common Stock Warrants Issuance of common stock warrants in connection with equipment financing loans Represents the equity impact of the issue of warrants by the reporting entity. Adjustments to Additional Paid in Capital, Temporary Equity Interest, Amount Series F amount interest Represents change in additional paid-in capital resulting from the interest amount on preferred stock. Modification of Stock Warrants Common stock warrant modification Represents the effect of modification in terms and conditions on stock warrants. Effect of Change in Par Value of Stock Change in par value Represents the effect of change in par value on equity of the reporting entity. Consolidated subsidiaries Consolidated Subsidiaries [Text Block] The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). This disclosure also includes information regarding variable interest entities (VIE) in aggregate, including how similar entities are aggregated, if separate reporting would not provide more useful information, distinguished between (1) VIEs that are not consolidated because the enterprise is not the primary beneficiary but has a significant variable interest or is the sponsor that holds a variable interest, and (2) VIEs that are consolidated. Presented in a manner that clearly and fully explains to financial statement users the nature and extent of an enterprise's involvement with variable interest entities. Series F amount Series F amount The entire disclosure for Series F convertible preferred stock. Series F Amount Disclosure [Text Block] Stock Warrants Disclosure [Text Block] Stock warrants The entire disclosure for the common stock warrants activity of the company. Conversion of Stock Warrants Conversion of convertible preferred stock warrants to common stock warrants The value of convertible preferred stock warrants converted to common warrants. Number of Targeted Therapeutic Oncology Candidates in Clinical Development Number of targeted therapeutic oncology candidates Represents the number of targeted therapeutic oncology candidates in clinical development of the entity. Represents the number of shares issued to underwriters under an over-allotment option. Stock Issued During Period Shares Issued to Underwriters under over Allotment Option Common stock issued to underwriters under an over-allotment option (in shares) Convertible Preferred Stock Warrant [Member] Convertible preferred stock warrants Represents the security that gives the holder the right to purchase preferred stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Sanofi [Member] Sanofi Represents the information pertaining to Sanofi. Phase Two Clinical Trials in Breast Cancer and Nonsmall Cell Lung Cancer [Member] Phase 2 clinical trials in breast cancer and non-small cell lung cancer Represents the information pertaining to dosing the first patients in Phase 2 clinical trials in breast cancer and non-small cell lung cancer. Phase Two Clinical Trials in Ovarian Cancer [Member] Phase 2 clinical trial in ovarian cancer Represents the information pertaining to dosing the first patient in a Phase 2 clinical trial in ovarian cancer. Available-for-sale Securities, Gross Unrealized Gains Unrealized Gains Development and Regulatory Milestones [Member] Development and regulatory milestone Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved. Sales Milestones [Member] Sales milestone Represents information pertaining to certain sales events on the basis of which certain milestones are achieved. Phase Three Clinical Trials in Pancreatic Cancer [Member] Phase 3 clinical trial in pancreatic cancer Represents the information pertaining to dosing the first patient in a Phase 3 clinical trial in pancreatic cancer. Pharma Engine Inc [Member] PharmaEngine Represents the information pertaining to PharmaEngine, Inc. Related Party Transactions Shares Purchased by Related Party Shares of common stock purchased by related party in connection with initial public offering Represents the number of shares of common stock purchased by a related party in connection with the initial public offering. Schedule of Shares of Common Stock Reserved for Future Issuance [Table Text Block] Schedule of shares reserved for future issuance Tabular disclosure of the shares of common stock reserved for future issuance by the entity. Stock Incentive Plan 2008 [Member] 2008 Plan Represents the details pertaining to 2008 Stock Incentive Plan as amended, a stock-based compensation plan. Stock Incentive Plan 2011 [Member] 2011 Plan Represents the details pertaining to 2011 Stock Incentive Plan, a stock-based compensation plan. Employee [Member] Employee Represents the details pertaining to the employees of the entity. Employee awards Non Employee [Member] Non-employee Represents the details pertaining to individuals other than employees of the entity. Disclosure of accounting policy for convertible preferred stock and convertible preferred stock warrants. Convertible Preferred Stock and Convertible Preferred Stock Warrants [Policy Text Block] Convertible Preferred Stock and Convertible Preferred Stock Warrants Schedule of Noncontrolling Interest [Table Text Block] Schedule of non-controlling interest in subsidiary Tabular disclosure of the information pertaining to the noncontrolling interest. Available For Sale Securities Expected Maturity Period Expected average maturities period of marketable securities classified as available-for-sale Represents the expected average maturity period of marketable securities classified as available-for-sale. Available For Sale Securities, Number of Securities Sold Number of securities sold Represents the number of available-for-sale-securities sold. Available For Sale Securities Reconciliation [Abstract] Available-for-sale securities Collaborative Arrangement Revenue Recognition [Abstract] Recognized revenue under collaboration agreements Available For Sale Securities in Unrealized Loss Positions Twelve Months or Longer Qualitative Disclosure Number of Positions Number of securities in unrealized loss position for greater than 12 months Disclosure regarding factors used to determine that the impairment of securities not categorized as either held-to-maturity securities or trading securities (hence equal to available-for-sale securities), where cost exceeds fair value, is not an other than temporary impairment (OTTI). This item contains disclosure of the number of investment positions for twelve months or longer in the available-for-sale investments determined to be temporarily impaired. Gain (Loss) Related to Settlement Settlement from former service provider Represents the amount of gain (loss) related to settlement from a former service provider. Achievement of Milestone [Axis] Information by categories of milestones achieved. Achievement of Milestone [Domain] Different categories of achievement of milestones. Collaborative Arrangement Upfront License Fee Received Upfront license fee received Represents the cumulative amount of nonrefundable, noncreditable upfront license fee received during the period under the terms of license and collaboration agreements. Upfront payment Represents the amount of revenue recognized from upfront payment received during the period under the terms of license and collaboration agreements. Collaborative Arrangement Revenue Recognized Upfront Payment Collaborative Arrangement Revenue Recognized Milestone Payment Milestone payment Represents the amount of revenue recognized from milestone payment received during the period under the terms of license and collaboration agreements. Collaborative Arrangement Revenue Recognized Development Services Development services Represents the amount of revenue recognized from development services fees received during the period under the terms of license and collaboration agreements. Collaborative Arrangement Revenue Recognized Manufacturing Services and Other Manufacturing services and other Represents the amount of revenue recognized from manufacturing services and other fees received during the period under the terms of license and collaboration agreements. Collaborative Arrangement Upfront Payment Obligation Upfront license fees paid Represents the cumulative amount of nonrefundable, noncreditable upfront license fees paid during the period under the terms of license and collaboration agreements. Maximum milestone payment obligation Collaborative Arrangement Maximum Milestone Payment Obligation Represents the cumulative obligation for milestone payment payable during the period under the terms of license and collaboration agreements. Collaborative Arrangement Milestone Payment Milestone payment Represents the amount of milestone payment made during the period under the terms of license and collaboration agreements. Collaboration Agreement Reimbursement of Research and Development Cost Research and development expenses reimbursed Represents the amount of reimbursed costs pertaining to research and development expenses under the terms of license and collaboration agreements. Summary of Significant Accounting Policies Represents the revenue recognized during the period under the terms of license and collaboration agreements. Collaborative Arrangement Revenue Recognized Total Collaboration Agreement Assets and Liabilities [Abstract] Accounts receivable and deferred revenue related to collaboration agreement Entity Well-known Seasoned Issuer Collaborative Arrangement [Abstract] Collaborative arrangement additional information Entity Voluntary Filers Collaborative Arrangement Milestone Payments Received Milestone payments received Represents the cumulative amount of milestone payment received during the period under the terms of license and collaboration agreements. Entity Current Reporting Status Operating Lease Amendment Additional Space Lease Term Lease term of additional space Represents the period of lease for additional space under the amended lease agreement. Entity Filer Category Collaborative Arrangement Expected Development Period Expected development period from the effective date of agreement Represents the expected development period from the effective date of agreement. Entity Public Float Maximum reimbursement for tenant improvements agreed by landlord Represents the maximum amount of tenant improvements agreed to be reimbursed by landlord under the lease agreement. Operating Leases Maximum Reimbursement for Tenant Improvements Entity Registrant Name Operating Leases Reimbursements Receivable for Tenant Improvements Tenant improvements related receivable Represents the amount receivable for tenant improvements agreed to be reimbursed by landlord under the lease agreement. Entity Central Index Key Collaborative Arrangements Reimbursement of Previously Billed Amount Previously billed amount the Company will reimburse Represents the previously billed amount the Company will reimburse the other party under the license and collaboration agreement. Collaborative Arrangements Previously Billed Amount Reimbursed Previously billed amount reimbursed by Company Represents the amount of contractual liability the Company reimbursed the other party under the license and collaboration agreement. Collaborative Arrangement Reduction in Earnings Due to Reimbursement of Previously Billed Amount Reduction in earnings due to reimbursement of previously billed amounts Represents the amount of reduction in earnings due to reimbursement of previously billed amount under the license and collaboration agreement. Other Nonoperating Income Expense [Policy Text Block] Disclosure of accounting policy for other income and expenses. Other Income (Expense) Entity Common Stock, Shares Outstanding Silver Creek Pharmaceuticals Inc [Member] Silver Creek Represents information pertaining to Silver Creek Pharmaceuticals Inc., a subsidiary of the entity Available-for-sale securities due after 1 year through 2 years, Amortized Cost Amount of available-for-sale debt securities at cost, net of adjustments, maturing after the first rolling twelve months through the second in the second rolling twelve months following the latest balance sheet presented. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings (less any cumulative-effect adjustments, as defined) and fair value hedge accounting adjustments. Available For Sale Securities Debt Maturities Rolling Year One Through Two Years Amortized Cost Available For Sale Securities Debt Maturities Rolling Year Two Through Three Years Amortized Cost Available-for-sale securities due after 2 years through 3 years, Amortized Cost Amount of available-for-sale debt securities at cost, net of adjustments, in the second rolling twelve months through the third in the second rolling twelve months following the latest balance sheet presented. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings (less any cumulative-effect adjustments, as defined) and fair value hedge accounting adjustments. Available For Sale Securities Debt Maturities Next Rolling Twelve Months Gross Unrealized Losses Available-for-sale securities due within 1 year, Unrealized Losses This item represents the gross unrealized losses for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities and maturing in the next rolling twelve months following the latest balance sheet presented. Available For Sale Securities Debt Maturities Next Rolling Twelve Months Gross Unrealized Gain Available-for-sale securities due within 1 year, Unrealized Gains This item represents the gross unrealized gains for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities and maturing in the next rolling twelve months following the latest balance sheet presented. Available For Sale Securities Debt Maturities after Rolling Year One Through Two Years Gross Unrealized Gain Available-for-sale securities due after 1 year through 2 years, Unrealized Gains This item represents the gross unrealized gains for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities and maturing after the first rolling twelve months through the second in the second rolling twelve months following the latest balance sheet presented. Available For Sale Securities Debt Maturities Rolling Year Two Through Three Years Gross Unrealized Gain Available-for-sale securities due after 2 years through 3 years, Unrealized Gains This item represents the gross unrealized gains for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities and maturing after second rolling twelve months through the third in the second rolling twelve months following the latest balance sheet presented. Available For Sale Securities Debt Maturities after Rolling Year One Through Two Years Gross Unrealized Losses Available-for-sale securities due after 1 year through 2 years, Unrealized Losses This item represents the gross unrealized losses for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities and maturing after the first rolling twelve months through the second in the second rolling twelve months following the latest following the latest balance sheet presented. Available For Sale Securities Debt Maturities Rolling Year Two Through Three Years Gross Unrealized Losses Available-for-sale securities due after 2 years through 3 years, Unrealized Losses This item represents the gross unrealized losses for securities, at a point in time, which are categorized neither as held-to-maturity nor trading securities and maturing after second rolling twelve months through the third in the second rolling twelve months following the latest following the latest balance sheet presented. Available For Sale Securities Debt Maturities after Rolling Year One Through Two Years Fair Value Available-for-sale securities due after 1 year through 2 years, Fair Value Amount of available-for-sale debt securities at fair value maturing after the first rolling twelve months through the second in the second rolling twelve months following the latest following the latest balance sheet presented. Accounts Payable and Accrued Liabilities, Current [Abstract] Accrued expenses and other Available-for-sale securities due after 2 years through 3 years, Fair Value Amount of available-for-sale debt securities at fair value maturing after second rolling twelve months through the third in the second rolling twelve months following the latest following the latest balance sheet presented. Available For Sale Securities Debt Maturities after Rolling Year Two Through Three Years Fair Value Available For Sale Securities Debt Maturities Gross Unrealized Gain [Abstract] Unrealized Gains Unrealized Losses Available For Sale Securities Debt Maturities Gross Unrealized Losses [Abstract] This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position after one year from balance sheet date through year two. Aggregate fair value, Due after 1 year through 2 years Available For Sale Securities Continuous Unrealized Loss Position after One Through Two Years Fair Value Available For Sale Securities Continuous Unrealized Loss Position after Two Through Three Years Fair Value Aggregate fair value, Due after 2 year through 3 years This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position after year two from balance sheet date through year three. Available For Sale Securities Continuous Unrealized Loss Position after One Through Two Years Aggregate Losses Unrealized losses, Due after 1 year through 2 years Amount of the excess of amortized cost basis over fair value of securities that have been in a loss position for after one year from balance sheet date through year two for securities which are categorized neither as held-to-maturity nor trading securities. Available For Sale Securities Continuous Unrealized Loss Position after Two Through Three Year Aggregate Losses Amount of the excess of amortized cost basis over fair value of securities that have been in a loss position after year two from balance sheet date through year three for securities which are categorized neither as held-to-maturity nor trading securities. Unrealized losses, Due after 2 years through 3 years Document Fiscal Year Focus Noncontrolling Interest Equity Preferred Fair Value As of the reporting date, the fair value of noncontrolling interests. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form. Non-controlling interest Document Fiscal Period Focus Proceeds from Issuance Initial Public Offering, Net of Offering Costs The cash inflow associated with the amount received from entity's first offering of stock to the public, net of offering costs. Net proceeds from initial public offering Proceeds from initial public offering, net of offering costs The cash inflow associated with the amount received from entity's first offering of stock to the public, net of offering costs, less the amount of deferred financing costs that were reclassified to equity. Proceeds from Issuance Initial Public Offering Net of Offering Costs Less Deferred Financing Costs Reclassified To Equity Schedule of Employee and Nonemployee Service Share Based Compensation Allocation of Recognized Period Costs [Text Block] Tabular disclosure of the allocation of equity-based compensation costs for employee and non-employee awards to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed. Schedule of recognized stock-based compensation expense Sale of Stock [Table] The different names of stock transactions and the different attributes of each transaction. Sale of Stock [Line Items] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Public Offering Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and nonemployees. Total stock-based compensation expense Allocated Share Based Compensation Expense Including Non Employees Operating Leases Future Minimum Payments Due Amendment Represents the amount of required minimum rental payments for leases having an initial or remaining non-cancelable term in excess of one year related to the lease amendment. Aggregate rent due over amended term of lease Purchased premiums and interest on available-for-sale securities Purchased Premiums and Interest on Available For Sale Securities The amount of purchased premiums and interest on available-for-sale securities. Number of common shares reserved for future issuance related to convertible preferred stock warrants. Convertible preferred stock warrants Convertible Preferred Stock Warrants Shares Reserved for Future Issuance Common Stock Warrants Shares Reserved for Future Issuance Number of common shares reserved for future issuance related to common stock warrants. Common stock warrants Common Stock Disclosure [Text Block] Common Stock The complete disclosure pertaining to the entity's common stock. Legal Entity [Axis] Hermes Bio Sciences Inc [Member] Hermes Represents information pertaining to HermesBioSciences,Inc., a privately-held biotechnology company developing lipidicnano-carriers to allow for targeted delivery of small molecule drugs, including chemotherapies, with the goal of improving cancer treatment safety and efficacy. Document Type Antibody Targeted Nanotherapeutic [Member] An antibody-targeted nanotherapeutic Represents an antibody-targeted nanotherapeutic development program which contains a chemotherapy drug. Nanotherapeutic [Member] Nanotherapeutic Represents the nanotherapeutic development program which contains a chemotherapy drug. Other Programs [Member] Other programs Represents the other development programs. Required disclosures pertaining to research and development program. Research and Development Program [Axis] Research and Development Program [Domain] Represents information by category of different research and development program. Debt Instrument Initial Advance Initial advance under Loan Agreement Represents the initial advance at closing under the debt agreement. Debt Instrument Additional Advance Additional term loan advance which is available at any time through December 15, 2012 Represents the additional advance that the entity may request at any time after the specified date through December 15, 2012. Life Sciences Tax Incentive Program 2011 [Member] Life Sciences Tax Incentive Program 2011 Represents information pertaining to tax incentives awarded in 2011 under the Life sciences Tax Incentive program. Tax Incentive Program [Line Items] Life Sciences Tax Incentive Program Tax Incentive Program Tax Incentive Awarded Tax incentive awarded Represents the amount of tax incentives awarded under the tax incentive and credit programs. Tax Incentive Program State Research and Development Tax Credits Monetized State research and development tax credits monetized Represents the state research and development tax credits monetized under the tax incentive and credit programs. Debt Instrument, Interest Rate Option [Axis] The alternative interest rate that may be used to calculate the interest rate of the debt instrument. Debt Instrument, Interest Rate Option [Domain] Identification of the alternative interest rate that may be used to calculate the interest rate of the debt instrument. Debt Instrument Interest Rate Alternative One [Member] Represents the first alternative interest rate. First alternative interest rate Debt Instrument Interest Rate Alternative Two [Member] Represents the second alternative interest rate. Second alternative interest rate Debt Instrument, Interest Rate, Stated Percentage Used as Basis for Calculation of Alternative Interest Rate Represents the stated interest rate used as the basis for calculation of the alternative interest rate. Stated percentage used as basis for calculation of alternative interest rate Debt Instrument, Description of Variable Rate Basis Added to Stated Percentage The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate, that is added to the stated percentage rate to calculate the alternative interest rate. Description of reference rate that is added to stated percentage rate in calculation of variable rate Debt Instrument, Basis Reduction on Variable Rate The percentage points subtracted from the alternative interest rate calculation used to compute the variable rate of the debt instrument. Percentage points subtracted from alternative interest rate Debt Instrument Gross Proceeds In One Or More Transactions Prior To Specified Date Amount of gross proceeds in one or more transactions prior to December 1, 2013 that the Company may elect to extend the interest-only period by six months Represents the amount of gross proceeds in one or more transactions prior to December 1, 2013 that the Company may elect to extend the interest-only period by six months so that the aggregate outstanding principal balance of the loan would be repaid in monthly installments starting on June 1, 2014 and continuing through November 1, 2016. Debt Instrument Interest only Payment Period Extension Extension period for interest only payments Represents the extension period for interest only payments as provided under the loan agreement. Accounts payable Accounts Payable, Current Amortization of premium on available-for-sale securities Accretion (Amortization) of Discounts and Premiums, Investments Accrued expenses and other Accrued Liabilities, Current Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income Additional paid-in capital Additional Paid in Capital Additional paid-in capital Additional Paid-in Capital [Member] Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock-based compensation Stock-based compensation expense for employee awards Allocated Share-based Compensation Expense Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Potentially dilutive securities excluded from computation of diluted weighted average shares Antidilutive Securities, Name [Domain] Antidilutive Securities [Axis] Asset-backed Securities [Member] Asset-backed security Current assets: Assets, Current [Abstract] Assets Assets [Abstract] Total current assets Assets, Current Total assets Assets Assets, Fair Value Disclosure [Abstract] Assets Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value Aggregate fair value, Due within 1 year Aggregate Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Abstract] Aggregate fair value of marketable securities in unrealized loss position Available-for-sale Securities, Fair Value Disclosure Investments Fair Value Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Fair Value Available-for-sale securities due within 1 year, Fair Value Available-for-sale Securities, Amortized Cost Basis [Abstract] Amortized Cost Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Losses [Abstract] Unrealized loss position Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract] Fair Value Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value Aggregate Fair Value Available-for-sale Securities, Gross Unrealized Losses Unrealized Losses Available-for-sale Securities, Debt Maturities, Amortized Cost Basis Amortized Cost Available-for-sale Securities, Debt Maturities, Next Rolling Twelve Months, Amortized Cost Basis Available-for-sale securities due within 1 year, Amortized Cost Available-for-sale Securities, Gross Realized Gain (Loss) Recognized gain on sale of marketable securities Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions Number of securities in unrealized loss position for less than 12 months Pro forma net loss per share available to common stockholders-basic (unaudited) (in dollars per share) Basic Earnings Per Share, Pro Forma Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Billed Contracts Receivable Accounts receivable, billed Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Contingent Consideration, at Fair Value, Noncurrent Contingent consideration Consolidated subsidiaries Acquired In-process Research and Development Business Acquisition [Line Items] Contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Capital lease obligations Capital Lease Obligations, Current Capital lease obligations Capital Lease Obligations, Noncurrent Cash and Cash Equivalents Disclosure [Text Block] Cash equivalents Cash equivalents Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash, Cash Equivalents and Restricted Cash Cash acquired in acquisition Cash Acquired from Acquisition Cash equivalents Cash, Cash Equivalents and Restricted Cash Unrestricted cash and cash equivalents and available-for-sale securities Cash, Cash Equivalents, and Short-term Investments Class of Stock [Domain] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] License and collaboration agreements Contractual matter Collaborative Arrangement Disclosure [Text Block] License and Collaboration Agreements Collaborative Arrangement [Member] License and Collaboration Agreements Collaborative Arrangements and Non-collaborative Arrangement Transactions [Domain] Collaborative Arrangements and Non-collaborative Arrangements [Axis] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies Commitments and contingencies (Note 10) Commitments and Contingencies. Common stock Common Stock [Member] Common stock, shares outstanding Common Stock, Shares, Outstanding Common stock, $0.01 par value: 138,500 and 200,000 shares authorized at December 31, 2011 and September 30, 2012, respectively; 11,834 and 94,029 shares issued and outstanding at December 31, 2011 and September 30, 2012, respectively Common Stock, Value, Issued Common stock, shares issued Common Stock, Shares, Issued Balance (in shares) Balance (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common Stock, Capital Shares Reserved for Future Issuance Shares reserved for future issuance Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Shares reserved for future issuance Retirement plan Compensation and Employee Benefit Plans [Text Block] Retirement plan Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive Income (Loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Comprehensive Income, Policy [Policy Text Block] Comprehensive Income (Loss) Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Consolidation, Policy [Policy Text Block] Principles of Consolidation Contingent Consideration Classified as Equity [Member] Contingent consideration Contractual liability Contractual Obligation, Due in Next Twelve Months Convertible preferred stock converted into common stock (in shares) Conversion of Stock, Shares Issued Conversion of Stock, Amount Converted Conversion of convertible preferred stock to common stock Convertible Preferred Stock, Shares Reserved for Future Issuance Conversion of Series B, Series C, Series D, Series E, Series F and Series G convertible preferred stock Convertible Preferred Stock [Member] Convertible preferred stock Conversion of Series B, Series C, Series D, Series E, Series F and Series G convertible preferred stock Corporate Debt Securities [Member] Corporate debt securities Costs and Expenses [Abstract] Operating expenses Costs and Expenses Total operating expenses Damages from Product Defects [Member] Quality control issues related to fill-finish manufacturing services Debt Instrument [Line Items] Loan and Security Agreement Schedule of Long-term Debt Instruments [Table] Fee paid Debt Instrument, Fee Amount Debt Disclosure [Text Block] Debt Debt Debt Instrument, Increase, Additional Borrowings Amount of unsecured note purchase agreement Stated interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Options to purchase common stock Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance Title of Individual [Axis] Deferred tax incentives Deferred Credits and Other Liabilities, Current Deferred tax incentives Deferred Credits and Other Liabilities, Noncurrent Deferred Charges, Policy [Policy Text Block] Deferred Financing Costs Deferred lease benefits Deferred Rent Credit, Noncurrent Deferred Revenue Deferred revenue Deferred financing costs Deferred Finance Costs, Current, Net Deferred lease benefits Deferred Rent Credit, Current Deferred Costs, Current [Abstract] Deferred Financing Costs Deferred revenues Deferred Revenue, Noncurrent Deferred revenues Deferred Revenue, Current Depreciation and amortization Depreciation, Depletion and Amortization Diluted Earnings Per Share Pro Forma Pro forma net loss per share available to common stockholders-diluted (unaudited) (in dollars per share) Director Director [Member] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Stock-Based Compensation Dividends, Preferred Stock, Cash Cash dividends payable to Series B convertible preferred stock holders Dividends Payable Dividends on Series B convertible preferred stock declared but not paid Dividends payable Dividends Payable, Current Earnings Per Share, Basic and Diluted [Abstract] Denominator: Earnings Per Share, Basic and Diluted Net loss per share available to common stockholders-basic and diluted (in dollars per share) Net loss per share available to common stock holders-basic and diluted Earnings Per Share [Text Block] Net Loss Per Common Share Net Loss Per Common Share Employee-related Liabilities, Current Payroll and related benefits Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Stock-based compensation Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Convertible preferred stock Equity Component [Domain] Convertible Preferred Stock and Convertible Preferred Stock Warrants Features of Convertible Preferred Stock [Abstract] Measurement Frequency [Axis] Fair Value, Hierarchy [Axis] Liability Class [Axis] Fair Value, Measurements, Recurring [Member] Recurring basis Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement Frequency [Domain] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value by Liability Class [Domain] Fair value of assets acquired in acquisition Fair Value of Assets Acquired Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issues Reclassification to common stock warrants Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets and liabilities measured at fair value on a recurring basis Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Fair Value, Inputs, Level 3 [Member] Level 3 Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss) Included in Other Income Unrealized gain/loss included in other income (expense) Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Roll-forward of the fair value of the convertible preferred stock warrants categorized as Level 3 instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule of fair value of convertible preferred stock warrants categorized as Level 3 instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value of Financial Instruments Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Financing [Domain] Financing [Axis] Intangible assets, net Finite-Lived Intangible Assets, Net Foreign Government Debt Securities [Member] Foreign government bond Gain (Loss) on Sale of Property Plant Equipment (Gain) loss on disposal of property and equipment General and Administrative Expense General and administrative General and Administrative Expense [Member] General and administrative Goodwill Goodwill Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and intangible assets, net Goodwill and Intangible Assets Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Goodwill and intangible assets, net Acquired In-process Research and Development In Process Research and Development, Policy [Policy Text Block] Condensed Consolidated Statements of Comprehensive Income (Loss) Income Tax Disclosure [Text Block] Income taxes Income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Net loss before income taxes and non-controlling interest Income Tax Expense (Benefit) Benefit from income taxes Accrued expenses and other Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Increase (Decrease) in Accounts Payable Accounts payable Deferred revenues Increase (Decrease) in Deferred Revenue Changes in operating assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Other assets and liabilities, net Increase (Decrease) in Other Operating Assets and Liabilities, Net Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Noncash interest expense Increase (Decrease) in Interest Payable, Net (Assignment) release of restricted cash Increase (Decrease) in Restricted Cash Accounts receivable Increase (Decrease) in Receivables Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] In-process research and development Indefinite-Lived Intangible Assets (Excluding Goodwill) IPR&D Interest Expense Interest expense Interest Paid Cash paid for interest Investment Income, Interest Interest income Initial public offering IPO [Member] Long-term Debt, Type [Domain] Long-term Debt, Type [Axis] Leases, Operating [Abstract] Operating leases Total current liabilities Liabilities, Current Fair value of liabilities assumed in acquisition Liabilities Assumed Liabilities, Current [Abstract] Current liabilities: Total liabilities Liabilities Liabilities, Convertible Preferred Stock, Non-controlling Interest and Stockholders' (Deficit) Equity Liabilities and Equity [Abstract] Liabilities, Fair Value Disclosure [Abstract] Liabilities Total liabilities, convertible preferred stock, non-controlling interest and stockholders' (deficit) equity Liabilities and Equity Aggregate principal amount available Line of Credit Facility, Maximum Borrowing Capacity Loss Contingencies [Table] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Marketable Securities, Policy [Policy Text Block] Marketable Securities Marketable Securities, Realized Gain (Loss) (Gain) loss on sale of marketable securities Marketable Securities [Abstract] Marketable Securities Marketable Securities, Current Available-for-sale securities Maximum [Member] Maximum Minimum [Member] Minimum Noncontrolling Interest [Table] Stockholders' Equity Attributable to Noncontrolling Interest Balance at the beginning of the period Balance at the end of the period Noncontrolling Interest [Line Items] Non-Controlling Interest Noncontrolling Interest, Ownership Percentage by Parent Ownership interest (as a percent) Money Market Funds, at Carrying Value Cash equivalents - money market funds Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Activity related to Non-Controlling Interest Nature of the Business Nature of Operations [Text Block] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net Cash Provided by (Used in) Continuing Operations Net increase (decrease) in cash and cash equivalents Net increase (decrease) in cash and cash equivalents Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net Income (Loss) Available to Common Stockholders, Basic Net loss available to common stockholders - basic Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Numerator - diluted: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Numerator - basic: Net Income (Loss) Available to Common Stockholders, Diluted Net loss available to common stockholders - diluted Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Net Income (Loss) Attributable to Parent Net loss attributable to Merrimack Pharmaceuticals, Inc. Net loss attributable to Merrimack Pharmaceuticals, Inc. Net Income (Loss) Attributable to Noncontrolling Interest Less net loss attributable to non-controlling interest Loss attributable to non-controlling interest Net loss attributable to Silver Creek Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Other income and expenses Nonoperating Income (Expense) [Abstract] Other Income (Expense) Noncontrolling Interest, Increase from Business Combination Ownership change in non-controlling interest Non-controlling interest Noncontrolling Interest [Member] Operating Leases, Rent Expense, Net Total rent expense Operating Income (Loss) Loss from operations Nature of the Business Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Other assets Other Assets, Noncurrent Goods and services Other Liabilities, Current Other Nonoperating Income (Expense) Other, net Plus: Unaccreted dividends on convertible preferred stock Other Preferred Stock Dividends and Adjustments Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Unrealized gain on available-for-sale securities Unrealized gain on available-for-sale securities Accrued Expenses and Other Other investing activities, net Payments for (Proceeds from) Other Investing Activities Deferred financing costs Payments of Stock Issuance Costs Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Payment of dividends on Series B convertible preferred stock Payments of Ordinary Dividends, Preferred Stock and Preference Stock Purchases of available-for-sale securities Payments to Acquire Marketable Securities Plan Name [Domain] Plan Name [Axis] Preferred Stock, Value, Issued Preferred stock, $0.01 par value: no shares and 10,000 shares authorized at December 31, 2011 and September 30, 2012, respectively; no shares issued or outstanding at December 31, 2011 and September 30, 2012, respectively Preferred Stock, Shares Authorized Preferred stock, shares authorized Authorized undesignated preferred stock (in shares) Preferred Stock [Text Block] Convertible preferred stock Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Preferred stock Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Reclassification Reclassification, Policy [Policy Text Block] Weighted-average common shares used in computing pro forma net loss per share available to common stockholders-diluted (unaudited) (in shares) Pro Forma Weighted Average Shares Outstanding, Diluted Proceeds from exercise of stock warrants Proceeds from Warrant Exercises Net proceeds from loan Proceeds from Issuance of Secured Debt Proceeds from issuance of convertible preferred stock, net of offering costs Proceeds from Issuance of Convertible Preferred Stock Proceeds from exercise of stock options Proceeds from Issuance of Common Stock Proceeds from maturities of available-for-sale securities Proceeds from Sale and Maturity of Available-for-sale Securities Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds received in advance of Series G issuance Proceeds from Sale of Available-for-sale Securities Gross proceeds from sale of marketable securities Proceeds from maturities or sales of marketable securities Proceeds from Sale and Maturity of Marketable Securities Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net loss Disposals of fully depreciated property and equipment Property, Plant and Equipment, Disposals Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Property and equipment, net Range [Axis] Range [Domain] Accounts receivable Receivables, Net, Current Redeemable Convertible Preferred Stock [Member] Series B-F convertible preferred stock Related Party Transactions Disclosure [Text Block] Related Party Transactions Related Party Transaction [Line Items] Related Party Transactions Related Party [Domain] Related Party Transactions Related Party [Axis] Principal payment of long-term debt Repayments of Long-term Debt Repayments of Long-term Capital Lease Obligations Principal payments on capital lease obligations Research and Development Expense Research and development Research and development expenses Research and Development Expense [Member] Research and development Restricted Cash and Cash Equivalents Restricted cash Restricted cash Restricted Cash and Cash Equivalents, Current Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings [Member] Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Collaboration revenues Revenues Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Exercisable at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected term Sale Leaseback Transaction, Net Proceeds Proceeds from sale-lease back Scenario, Unspecified [Domain] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of assets and liabilities measured at fair value on a recurring basis Schedule of revenue recognized and accounts receivable and deferred revenue under collaborative arrangements Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of stock option activity Schedule of Comprehensive Income (Loss) [Table Text Block] Schedule of comprehensive loss from operations Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of assumptions used to calculate fair value of options granted Schedule of Available-for-sale Securities [Table] Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of computation of basic and diluted net loss per share available to common stockholders Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of potentially dilutive securities excluded from computation of diluted weighted average shares Schedule of accrued expenses and other Schedule of Accrued Liabilities [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Unrealized Loss on Investments [Table Text Block] Schedule of marketable securities in an unrealized loss position Schedule of Available-for-sale Securities [Line Items] Available-for-sale securities Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Schedule of available-for-sale securities Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Related Party Transactions, by Related Party [Table] Loan and Security Agreement with Hercules Technology Growth Capital, Inc. Secured Debt [Member] Stock-based compensation Share-based Compensation Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized Additional common stock available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Vesting period Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Stock options issued (in shares) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock-based compensation Share Price Public offering price (in dollars per share) Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Expected dividend yield (as a percent) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Exercisable at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Common stock available for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Assumptions used to estimate grant date fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Vested and expected to vest at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding at the beginning of the period (in dollars per share) Outstanding at the end of the period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Outstanding at the beginning of the period (in dollars) Outstanding at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Vested and expected to vest at the end of the period (in dollars) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest at the end of the period (in dollars per share) Stock-based compensation expense for non-employee awards Share-based Goods and Nonemployee Services Transaction, Expense Statement [Table] Scenario [Axis] Statement Statement [Line Items] Consolidated statements of convertible preferred stock, non-controlling interest and stockholders' deficit Condensed Consolidated Statements of Cash Flows Equity Components [Axis] Condensed Consolidated Balance Sheets Class of Stock [Axis] Stock Issued During Period, Shares, Period Increase (Decrease) Stock Issued During Period, Shares, Acquisitions Issuance of common stock in connection with acquisition (in shares) Stock Options [Member] Options to purchase common stock Equity compensation plans Exercise of employee stock options Stock Issued During Period, Value, Stock Options Exercised Stock Issued During Period, Value, Acquisitions Issuance of common stock in connection with acquisition Stock Issued During Period, Value, New Issues Issuance of Series F stock Stock Issued During Period, Value, Conversion of Convertible Securities Issuance of Series C stock as a result of warrant exercises Stock Issued Fair value of equity issued in acquisition Aggregate shares of common stock sold in connection with initial public offering Stock Issued During Period, Shares, New Issues Aggregate common stock issued In connection with initial public offering (in shares) Exercise of employee stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Issuance of Series C stock as a result of warrant exercises (in shares) Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total stockholders' (deficit) equity Stockholders' (deficit) equity: Stockholders' Equity Attributable to Parent [Abstract] Total stockholders' (deficit) equity Stockholders' Equity Attributable to Parent Common Stock Stockholders' Equity, Period Increase (Decrease) Subsequent Events [Text Block] Subsequent Events Subsequent Events Subsequent Event Type [Domain] Subsequent Events Subsequent Event [Line Items] Loan and Security Agreement Subsequent Event Type [Axis] Subsequent Event [Table] Subsequent event Subsequent Event [Member] Supplemental disclosure of cash flows Supplemental Cash Flow Information [Abstract] Temporary Equity, Carrying Amount, Attributable to Parent Convertible preferred stock Title of Individual with Relationship to Entity [Domain] Type of Arrangement and Non-arrangement Transactions [Axis] Unbilled Contracts Receivable Accounts receivable, unbilled Use of Estimates, Policy [Policy Text Block] Use of Estimates US Government Agencies Debt Securities [Member] U.S. Government agencies securities U.S. treasury securities US Treasury Securities [Member] Valuation Allowance, Deferred Tax Asset, Change in Amount Noncash benefit on release of tax valuation allowance Common stock warrants Warrant [Member] Stock warrants Common stock warrants Warrants and Rights Outstanding Weighted-average common shares used in computing pro forma net loss per share available to common stockholders-basic (unaudited) (in shares) Weighted Average Basic Shares Outstanding, Pro Forma Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted-average common shares used in computing net loss per share available to common stockholders-basic and diluted Weighted-average common shares-basic and diluted Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum Minimum stated percentage rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum Maximum stated percentage rate (as a percent) Debt Instrument, Description of Variable Rate Basis Description of reference rate that is added to stated percentage rate in calculation of variable rate